Oligonucleotide Manufacturing: Take Control Of Your Process

Source: Cytiva

By Lucy Cook, Ph.D. Global Marketing Manager for Nucleic Acid Therapeutics

Scientist Using Bioreactor GettyImages-532549174

If you are involved in the development of antisense oligonucleotides (ASOs), siRNA, or other oligonucleotide therapeutics, you are likely well aware of the significant potential these molecules hold. To effectively tap into this potential, it is crucial to focus on key aspects during the early stages of process development for oligonucleotide therapeutics. The decisions made at this stage can profoundly impact various aspects later on, including speed to market, regulatory acceptance, manufacturing costs, and the ability to achieve process sustainability at large scale.

Oligonucleotide therapeutics are synthetic strands of DNA or RNA designed to specifically target and bind to particular gene or protein sequences. Their high specificity makes them promising candidates for treating conditions such as cancers and genetic diseases. Additionally, they are used in applications such as CRISPR-mediated gene editing.

Here, we outline five essential factors that contribute to success in oligo synthesis, scale-up, and manufacturing.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online